IOVANCE BIOTHERAPEUTICS, INC. Net Cash Provided by (Used in) Financing Activities in USD from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Iovance Biotherapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Iovance Biotherapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $143M, a 26% decline year-over-year.
  • Iovance Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $391M, a 15.6% decline from 2023.
  • Iovance Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $463M, a 143% increase from 2022.
  • Iovance Biotherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $190M, a 20.5% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

IOVANCE BIOTHERAPEUTICS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $143M -$50.3M -26% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q1 2024 $194M -$64.6M -25% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q1 2023 $258M +$257M +18120% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $1.42M -$48.9M -97.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 $50.4M +$46.5M +1214% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $3.83M +$3.84M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 -$2K* -$170M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q1 2018 $170M +$169M +44177% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q1 2017 $383K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q1 2014 $543K +$243K +80.8% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-14
Q1 2013 $300K +$50K +20% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q1 2012 $250K +$205K Jan 1, 2012 Mar 31, 2012 10-Q 2013-10-23
Q1 2011 $45K* Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-15

IOVANCE BIOTHERAPEUTICS, INC. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $391M -$72.3M -15.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 $463M +$273M +143% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 $190M -$49.1M -20.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 $239M -$337M -58.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $576M +$570M +9302% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $6.13M -$418M -98.6% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $424M +$366M +623% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $58.7M -$38.2M -39.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-25
2016 $96.9M +$18.6M +23.8% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $78.3M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2013 $23.3M +$21.6M +1249% Jan 1, 2013 Dec 31, 2013 10-K 2014-03-28
2012 $1.73M -$3.76M -68.5% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-28
2011 $5.49M +$3.58M +188% Jan 1, 2011 Dec 31, 2011 10-K 2013-09-23
2010 $1.91M Jan 1, 2010 Dec 31, 2010 10-K 2012-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.